What is CellMEAT?
CellMEAT operates at the intersection of biotechnology and food science, specializing in the cultivation of meat directly from animal cells. By bypassing the traditional slaughter process, the company creates high-quality, nutrient-dense protein products that mirror the texture and flavor profile of conventional meat. Their flagship product, GogiMEAT, represents a significant technological breakthrough in tissue engineering, allowing for the efficient production of cultured meat at scale. As a key innovator in the South Korean food-tech landscape, CellMEAT is strategically positioned to disrupt the global meat supply chain, offering a scalable solution to the environmental and ethical challenges associated with industrial animal farming.
How much funding has CellMEAT raised?
CellMEAT has raised a total of $33.6M across 3 funding rounds:
Other Financing Round
$4.5M
Series A
$8.1M
Series A
$21M
Other Financing Round (2021): $4.5M with participation from PSG Asset Management, Nau Ib Capital, DT Investments, BNK Venture Capital, and Ryu Kyung
Series A (2022): $8.1M led by Ryukyung PSG., BNK VENTURE CAPITAL, NauIB, and Strong Ventures
Series A (2023): $21M supported by Daewoo Healthcare, Genting Ventures, and NH Venture Investment
Key Investors in CellMEAT
BNK Venture Capital
A South Korean investment firm specializing in early-stage and growth-stage capital, focusing on high-potential technology and biotech ventures.
Nau IB Capital
A private equity and venture capital firm that provides strategic financial support to companies within the industrial and technology sectors.
DT Investments
A venture capital entity dedicated to backing innovative startups with a focus on disruptive technologies and sustainable business models.
What's next for CellMEAT?
With the recent influx of capital, CellMEAT is poised to expand its operational footprint and refine its production processes to achieve price parity with conventional meat. The strategic roadmap includes scaling manufacturing capabilities, navigating complex regulatory frameworks for food safety, and initiating market entry strategies for both domestic and international distribution. As the company moves into its next phase of growth, the focus will remain on optimizing cell culture media costs and enhancing the sensory attributes of its cultured protein offerings. Investors are closely monitoring the firm's ability to transition from pilot-scale production to mass-market availability, a critical milestone for the long-term viability of the cellular agriculture industry.
See full CellMEAT company page
